185 related articles for article (PubMed ID: 33609168)
1. The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies.
Manceau C; Fromont-Hankard G; Beauval JB; Lesourd M; Almeras C; Bajeot AS; Gautier JR; Soulié M; Loison G; Salin A; Tollon C; Malavaud B; Roumiguié M; Ploussard G
World J Urol; 2021 Sep; 39(9):3315-3321. PubMed ID: 33609168
[TBL] [Abstract][Full Text] [Related]
2. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
[TBL] [Abstract][Full Text] [Related]
3. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.
Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
World J Urol; 2020 Mar; 38(3):663-671. PubMed ID: 31197523
[TBL] [Abstract][Full Text] [Related]
4. Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery.
Ploussard G; Manceau C; Beauval JB; Lesourd M; Almeras C; Gautier JR; Loison G; Salin A; Soulié M; Tollon C; Malavaud B; Roumiguié M
World J Urol; 2020 Oct; 38(10):2493-2500. PubMed ID: 31838560
[TBL] [Abstract][Full Text] [Related]
5. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
[TBL] [Abstract][Full Text] [Related]
6. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis.
Kesch C; Pantea V; Soeterik T; Marquis A; la Bombarda G; Morlacco A; Barletta F; Radtke JP; Darr C; Preisser F; Zattoni F; Marra G; van den Bergh RCN; Hadaschik B; Gandaglia G;
World J Urol; 2023 Feb; 41(2):427-434. PubMed ID: 36534151
[TBL] [Abstract][Full Text] [Related]
7. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
[TBL] [Abstract][Full Text] [Related]
8. A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.
Diamand R; Oderda M; Al Hajj Obeid W; Albisinni S; Van Velthoven R; Fasolis G; Simone G; Ferriero M; Roche JB; Piechaud T; Pastore A; Carbone A; Fiard G; Descotes JL; Marra G; Gontero P; Altobelli E; Papalia R; Kumar P; Eldred-Evans D; Giacobbe A; Muto G; Lacetera V; Beatrici V; Roumeguere T; Peltier A
World J Urol; 2019 Oct; 37(10):2109-2117. PubMed ID: 30652213
[TBL] [Abstract][Full Text] [Related]
9. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study.
Diamand R; Hollans M; Lefebvre Y; Sirtaine N; Limani K; Hawaux E; Abou Zahr R; Mattlet A; Albisinni S; Roumeguère T; Peltier A
Urol Oncol; 2022 May; 40(5):192.e11-192.e17. PubMed ID: 35236622
[TBL] [Abstract][Full Text] [Related]
10. Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies.
Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
Urology; 2020 Mar; 137():126-132. PubMed ID: 31899229
[TBL] [Abstract][Full Text] [Related]
11. Impact of Magnetic Resonance Imaging Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-analysis.
Weinstein IC; Wu X; Hill A; Brennan D; Omil-Lima D; Basourakos S; Brant A; Lewicki P; Al Hussein Al Awamlh B; Spratt D; Bittencourt LK; Scherr D; Zaorsky NG; Nagar H; Hu J; Barbieri C; Ponsky L; Vickers AJ; Shoag JE
Eur Urol Oncol; 2023 Aug; 6(4):355-365. PubMed ID: 37236832
[TBL] [Abstract][Full Text] [Related]
12. The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
Gaffney CD; Tin AL; Fainberg J; Fine S; Jibara G; Touijer K; Eastham J; Scardino P; Laudone V; Vickers AJ; Ehdaie B
Cancer; 2023 Dec; 129(23):3790-3796. PubMed ID: 37584213
[TBL] [Abstract][Full Text] [Related]
13. The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology.
Sorce G; Stabile A; Pellegrino F; Mazzone E; Mattei A; Afferi L; Serni S; Minervini A; Roumiguiè M; Malavaud B; Valerio M; Rakauskas A; Marra G; Gontero P; Porpiglia F; Guo H; Zhuang J; Gandaglia G; Montorsi F; Briganti A
World J Urol; 2024 Apr; 42(1):248. PubMed ID: 38647689
[TBL] [Abstract][Full Text] [Related]
14. Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
Ren J; Melamed J; Taneja SS; Wysock JS; Huang WC; Lepor H; Deng FM
Prostate; 2023 Mar; 83(4):323-330. PubMed ID: 36461793
[TBL] [Abstract][Full Text] [Related]
15. Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
He Y; Shen Q; Fu W; Wang H; Song G
Prostate; 2022 Aug; 82(11):1125-1132. PubMed ID: 35538399
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study.
Ploussard G; Beauval JB; Lesourd M; Manceau C; Almeras C; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
World J Urol; 2020 Jul; 38(7):1735-1740. PubMed ID: 31612251
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
[TBL] [Abstract][Full Text] [Related]
19. Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies.
Maxeiner A; Nest AM; Stephan C; Cash H; Baur ADJ; Fischer T; Kilic E; Piper SK; Nowak CP; Busch J; Miller K; Mang J
Urol Int; 2020; 104(3-4):205-213. PubMed ID: 31801153
[TBL] [Abstract][Full Text] [Related]
20. Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance Imaging.
Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
J Urol; 2019 Dec; 202(6):1182-1187. PubMed ID: 31246548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
